[Thrombocytic hemostasis in hypertensive patients with metabolic syndrome and its correction with lovastatin].
The objective of the study was to evaluate the efficiency of lovastatin correction of dyslipidemia and impaired intravascular platelet activity (IPA) in patients with arterial hypertension (AH) concurrent with metabolic syndrome (MS). Eighteen patients were given lovastatin for a month. The time course of changes in anthropometric parameters, blood lipid spectrum, plasma and lipid peroxidation, antioxidative protectiveness of the liquid blood part and platelets, and IPA were assessed. The results were processed by Student's test and correlation analysis. Lovastin was ascertained to correct dyslipoproteinemia and peroxidation syndrome and to optimize the intrathrombocytic mechanisms responsible for their function regulation in patients with AH + MS. Lovastatin inhibits in vivo increased platelet activity. These effects may be stabilized during its use. Body weight loss and diminished insulin resistance in patients with AH concurrent MS require long use of lovastatin along with low-calorie diet and exercises.
Medvedev
I N
IN
Gromnatskiĭ
N I
NI
Volobuev
I V
IV
Osipova
V M
VM
Dement'ev
V I
VI
Storozhenko
M V
MV
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D015444:Exercise; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications*; D015227:Lipid Peroxidation; D008148:Lovastatin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy*; D008875:Middle Aged; D013997:Time Factors
D000924:Anticholesteremic Agents; D008148:Lovastatin